Atea Pharmaceuticals stockholders elect three Class II directors, approve 'one year' say-on-pay frequency

Atea Pharmaceuticals, Inc.

Elected Bruno Lucidi, Polly A. Murphy, and Bruce Polsky as Class II directors (over 55.7M votes each, no broker non-votes included).
Advisory vote on executive compensation frequency: ONE year approved with 59,857,505 votes for (99.4% of votes cast).
Ratification of KPMG LLP as independent auditor for 2022 passed with 71,630,493 votes for, 281,592 against, 35,490 abstain.
Approximately 86.41% of outstanding shares were represented at the meeting (71,947,575 shares of common stock).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.